|
Ramin (Ron) Najafi ((ペルシア語:رامین نجفی )) was born in Tehran, Iran in 1958. He completed his primary education and received his high school diploma from Alborz High School in Tehran. In 1976, he immigrated to the United States to pursue his passion of becoming a chemist. He began his undergraduate degree in pharmacy at the University of Pittsburgh, Pennsylvania. After earning a B.S. and M.S. in chemistry under the guidance of Professor John Soderquist at the University of San Francisco, he then received his Ph.D. at University of California at Davis under the tutelage of Prof. Emeritus George Zweifel(). Post-Ph.D., He worked at Sigma-Aldrich, Rhone Poulenc Rorer (now Sanofi), and PerkinElmer-Applied Biosystems before leaving to found CP Lab Safety and NovaBay Pharmaceuticals. Najafi is an innate innovator. With more than 50 patents & pending patent applications, including a class of non-antibiotic, antimicrobial compounds named Aganocides®. The leading molecule of this aganoicide family of compounds, auriclosene, has a broad spectrum of antimicrobial activity against bacteria, viruses and fungi. Auriclosene is chemically stable and has an extremely low probability of developing resistance. NovaBay is developing a formulation of Auriclosene to be used against eye, skin, and urinary tract infections. These products are currently in FDA monitored clinical trials. The products are intended to replace current classical antibiotics used in eye, skin, and urinary tract infections. Najafi currently serves as CEO and Chairman of NovaBay Pharmaceutical (www.novabay.com). ==Life and career== Having immigrated from Iran to study in 1976, Najafi's future plans were thrown into disarray by the 1979 Iranian Revolution. Under the guidance of Professor John Soderquist at University of San Francisco, he earned a B.S. and M.S. in chemistry, and then received his Ph.D. at University of California at Davis under the tutelage of Prof. Emeritus George Zweifel. He worked at Sigma-Aldrich, Rhone Poulenc, and PerkinElmer before leaving to found Calpac Labs (now CP Lab Safety) and NovaCal Pharmaceuticals (now NovaBay Pharmaceuticals) Najafi was recognized by PharmaVoice 100 as one of 100 most influential leaders of 2008. '' He is a tenacious leader and innovative developer of new molecules recognized for creating a paradigm shift in how antibiotics are used''. He is an inventor on more than 50 patents & pending patents applications, including a class of non-antibiotic, antimicrobial compounds named Aganocides. The lead molecule, Auriclosene has broad spectrum of activity against bacteria (Wang 2011), viruses (Yoon 2011), and fungi (Ghannoum 2013), is chemically stable (Wang 2008), and has extremely low probability of developing resistance (D’Lima 2012). Currently, auriclosene is in four clinical trials for treatment of adenoviral conjunctivitis, bacterial conjunctivitis, impetigo and urinary catheter blockage and encrustation (Gottardi 2013).〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ron Najafi」の詳細全文を読む スポンサード リンク
|